Cancer Drugs Under Development

Publication
Article
OncologyONCOLOGY Vol 9 No 2
Volume 9
Issue 2

According to the Pharmaceutical Research and Manufacturers of America, as of 1993, 124 cancer drugs were in some stage of development at 49 pharmaceutical companies and the National Cancer Institute. The report was based on an NCI survey.

According to the Pharmaceutical Research and Manufacturers ofAmerica, as of 1993, 124 cancer drugs were in some stage of developmentat 49 pharmaceutical companies and the National Cancer Institute.The report was based on an NCI survey. At least 16 of the upcomingcancer drugs are genetically engineered. Since many of these drugsare targeted to more than one type of cancer, 223 research projectsare ongoing.

Articles in this issue
New Noninvasive Test May Improve Breast Cancer Diagnosis and Reduce Unnecessary Biopsies
Cancer Drugs Under Development
Early Results of RTOG Small-Cell Lung Cancer Trial
The Economics of Oncology: Health System Reform and Clinical Research
An Update on the Pros and Cons of Preventive Mastectomy
The Effect of Tamoxifen on the Endometrium
Commentary (Look): The Effect of Tamoxifen on the Endometrium
Commentary (Kimmick/Muss): The Effect of Tamoxifen on the Endometrium
Management of Papillary Thyroid Cancer
Commentary (Cady): Management of Papillary Thyroid Cancer
The Management of Early Ovarian Cancer
Commentary (Markman): The Management of Early Ovarian Cancer
Commentary (Thigpen): The Management of Early Ovarian Cancer
Recent Videos
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content
Data from the INTERLACE trial shows induction chemotherapy followed by chemoradiotherapy prolongs overall survival in locally advanced cervical cancer.

Induction Chemotherapy Combination Boosts PFS/OS in Cervical Cancer

Tim Cortese
November 3rd 2024
Article

Data from the INTERLACE trial shows induction chemotherapy followed by chemoradiotherapy prolongs overall survival in locally advanced cervical cancer.

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Empowering Awareness to Address Rising Gynecological Cancer Incidence

Ginger J. Gardner, MD, FACOG
October 28th 2024
Podcast

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Inavolisib-based therapy reaches the primary end point of the phase 3 INAVO120 study among patients with PIK3CA-mutated breast cancer.

Inavolisib-Based Therapy Boosts Progression-Free Survival in Breast Cancer

Tim Cortese
November 1st 2024
Article

Inavolisib-based therapy reaches the primary end point of the phase 3 INAVO120 study among patients with PIK3CA-mutated breast cancer.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Atezolizumab/Matched-Targeted Therapy Improves OS in Anaplastic Thyroid Cancer

Atezolizumab/Matched-Targeted Therapy Improves OS in Anaplastic Thyroid Cancer

Tim Cortese
November 1st 2024
Article

Patients with anaplastic thyroid cancer had a significant boost to overall survival with atezolizumab and targeted therapy.

Findings speak to the need of cultural, racial, and ethnic inclusion when designing breast cancer trials and developing patient-reported outcome measures.

Study Shows Post-Mastectomy Disparities in Breast Cancer Minority Groups

Russ Conroy
October 31st 2024
Article

Findings speak to the need of cultural, racial, and ethnic inclusion when designing breast cancer trials and developing patient-reported outcome measures.